HLA-A11 epitope loss isolates of Epstein-Barr virus from

Science 260, 98-100 DOI: 10.1126/science.7682013

Citation Report

#	Article	IF	CITATIONS
1	Herpesvirus evasion of T-cell immunity. , 2007, , 1117-1136.		4
2	CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. Current Opinion in Immunology, 1993, 5, 484-491.	5.5	45
3	Viral immunopathology of human tumors. Current Opinion in Immunology, 1993, 5, 693-700.	5.5	28
4	Multistep evolution of B-cell-derived tumors in humans and rodents. Gene, 1993, 135, 189-196.	2.2	18
5	Natural selection at work on the surface of virus-infected cells. Science, 1993, 260, 1771-1772.	12.6	14
6	Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood, 1993, 82, 2937-2942.	1.4	202
7	The role of infection in inflammatory arthritis. QJM - Monthly Journal of the Association of Physicians, 1994, , .	0.5	2
8	Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood, 1994, 84, 4053-4060.	1.4	112
9	Role of EBV and Ig/myc Translocation in Burkitt Lymphoma. Antibiotics and Chemotherapy, 1994, 46, 110-116.	0.5	9
10	How Dna Viruses Perturb Functional Mhc Expression To Alter Immune Recognition. Advances in Cancer Research, 1994, 63, 117-209.	5.0	74
11	Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature, 1994, 369, 407-410.	27.8	572
12	Fibromyalgia syndrome: a pain modulation disorder related to altered limbic function?. Bailliere's Clinical Rheumatology, 1994, 8, 777-800.	1.0	5
13	Generation of HLA-B55 restricted T lymphocyte mediated cytotoxicity against autologous LCL. Molecular Immunology, 1994, 31, 59-63.	2.2	0
14	Epstein-Barr virus: adaptation to a life within the immune system. Trends in Microbiology, 1994, 2, 125-130.	7.7	120
15	Immune Response against Tumors. Advances in Immunology, 1994, 57, 281-351.	2.2	71
16	Characterization of the Epstein-Barr virus Fp promoter. Virology, 1995, 206, 183-195.	2.4	36
17	EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. British Journal of Haematology, 1995, 91, 938-940.	2.5	20
18	Prevalence of precore-defective mutant of hepatitis B virus in HBV carriers. Journal of Medical Virology, 1995, 46, 397-402.	5.0	29

ATION RE

	CITATION N	LEPORT	
#	Article	IF	CITATIONS
19	Immune responses against multiple epitopes. Journal of Theoretical Biology, 1995, 175, 325-353.	1.7	60
20	Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. European Journal of Immunology, 1995, 25, 102-110.	2.9	39
21	HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding. European Journal of Immunology, 1995, 25, 728-732.	2.9	39
22	Epstein-barr virus (EBV) in malaysian upper-aerodigestive-tract lymphoma: Incidence and sub-type. International Journal of Cancer, 1995, 61, 327-332.	5.1	24
23	Nasal and nasal-type T/NK cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus. Histopathology, 1995, 27, 581-583.	2.9	86
24	A Genetic Herd-Immunity Model for the Maintenance of MHC Polymorphism. Immunological Reviews, 1995, 143, 263-292.	6.0	75
25	The ecology and pathology of Epsteinâ€Barr virus. Immunology and Cell Biology, 1995, 73, 489-504.	2.3	21
26	Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature, 1995, 375, 606-611.	27.8	342
27	Pathogen-Based Models Favoring MHC Genetic Diversity. Immunological Reviews, 1995, 143, 181-197.	6.0	104
28	Antagonists or altruists: do viral mutants modulate T-cell responses?. Trends in Immunology, 1995, 16, 432-436.	7.5	26
29	Viral mutations, TCR antagonism and escape from the immune response. Current Opinion in Immunology, 1995, 7, 524-531.	5.5	56
30	Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Immunologic Research, 1995, 14, 77-97.	2.9	15
31	The influence of immunity on virus evolution. , 1995, , 150-164.		1
32	Epstein-Barr Virus Coinfection and Recombination in Non-Human Immunodeficiency Virus-Associated Oral Hairy Leukoplakia. Journal of Infectious Diseases, 1995, 171, 1122-1130.	4.0	59
33	Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2755-2759.	7.1	338
34	Virus escape from immune control: mechanisms of persistence within the host. Research in Virology, 1995, 146, 267-271.	0.7	1
35	Differences in peptide binding of DR11 and DR13 microvariants demonstrate the power of minor variation in generating DR functional diversity. Human Immunology, 1995, 43, 101-112.	2.4	9
36	Molecular Epidemiology of Epstein–Barr Virus Infection. Advances in Cancer Research, 1995, 67, 197-255.	5.0	67

	CITATION	LFORT	
#	ARTICLE Compartmentalization of B-cell antigen receptor functions. Molecular Immunology, 1996, 33, 769-775.	IF 2.2	CITATIONS 2
38	Introduction: Presentation of viral antigens to cytotoxic T cells. Seminars in Virology, 1996, 7, 1-2.	3.9	4
39	Immunobiology of cytotoxic T-cell resistant virus variants: studies on lymphocytic choriomeningitis virus (LCMV). Seminars in Virology, 1996, 7, 3-11.	3.9	7
40	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. Seminars in Virology, 1996, 7, 23-30.	3.9	8
41	Cytotoxic T-cell antagonism in HIV-1. Seminars in Virology, 1996, 7, 31-39.	3.9	15
42	Strategies of immunoescape in Epstein-Barr virus persistence and pathogenesis. Seminars in Virology, 1996, 7, 75-82.	3.9	9
43	Immune responses against multiple epitopes: a theory for immunodominance and antigenic variation. Seminars in Virology, 1996, 7, 83-92.	3.9	30
44	Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery, 1996, 119, 544-551.	1.9	74
45	Immunology Taught by Viruses. Science, 1996, 271, 173-178.	12.6	645
46	Population Dynamics of Immune Responses to Persistent Viruses. Science, 1996, 272, 74-79.	12.6	1,060
47	Strategies Involved in Developing an Effective Vaccine for EBV-Associated Diseases. Advances in Cancer Research, 1996, 69, 213-245.	5.0	52
48	Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. European Journal of Immunology, 1996, 26, 1875-1883.	2.9	60
49	Detection of a nuclear antigen 2 (EBNA2)-variant Epstein-Barr virus strain in two siblings with fatal lymphoproliferative disease. , 1996, 48, 114-120.		7
50	Cytotoxic T lymphocyte responses to Epstein-Barr virus. Current Opinion in Immunology, 1996, 8, 492-497.	5.5	71
51	Infection $\hat{a} \in $ by the new genetics. Journal of Infection, 1996, 33, 1-5.	3.3	6
52	Activation of epitopeâ€specific memory cytotoxic T lymphocyte responses by synthetic peptides. Clinical and Experimental Immunology, 1996, 105, 369-375.	2.6	10
53	Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis Journal of Experimental Medicine, 1996, 184, 1815-1824.	8.5	82
54	Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology, 1997, 115, 55-66.	1.5	40

#	Article	IF	Citations
55	Role of Cellular Immunity in Protection against HIV Infection**This article was accepted for publication on 31 October 1996 Advances in Immunology, 1997, 65, 277-346.	2.2	107
56	HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION. Annual Review of Immunology, 1997, 15, 405-431.	21.8	706
57	ESCAPE OF HUMAN IMMUNODEFICIENCY VIRUS FROM IMMUNE CONTROL. Annual Review of Immunology, 1997, 15, 271-296.	21.8	315
58	The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses. Trends in Microbiology, 1997, 5, 64-69.	7.7	8
59	Differential immunogenicity of Epstein-Barr virus (EBV) encoded growth transformation-associated antigens in a murine model system. European Journal of Cancer, 1997, 33, 912-917.	2.8	13
60	Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. European Journal of Immunology, 1997, 27, 3166-3173	2.9	43
61	Modulation of Antigen Processing and Presentation by Persistent Virus Infections and in Tumors. Human Immunology, 1997, 54, 104-116.	2.4	15
62	Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94. 9848-9853.	7.1	191
63	Epitope-dependent Selection of Highly Restricted or Diverse T Cell Receptor Repertoires in Response to Persistent Infection by Epstein-Barr Virus. Journal of Experimental Medicine, 1997, 186, 83-89.	8.5	91
64	High frequency of Epstein-Barr virus (EBV) lymphoblastoid cell line-reactive lymphocytes in cord blood: evaluation of cytolytic activity and IL-2 production. Clinical and Experimental Immunology, 1997, 107, 312-320.	2.6	29
65	Mechanisms of viral clearance and persistence. Journal of Viral Hepatitis, 1997, 4, 16-24.	2.0	23
66	Human NK cells: their ligands, receptors and functions. Immunological Reviews, 1997, 155, 119-125.	6.0	75
67	Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunological Reviews, 1997, 157, 195-216.	6.0	169
68	How Viruses Escape from Cytotoxic T Lymphocytes: Molecular Parameters and Players. Virology, 1997, 234, 179-185.	2.4	86
69	Polymorphism of chicken CD8-alpha, but not CD8-beta. Immunogenetics, 1997, 46, 396-401.	2.4	31
70	T cell therapy of human CMV and EBV infection in immunocompromised hosts. , 1997, 7, 181-192.		91
71	Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. , 1997, 72, 614-618.		11
72	The role of anchor residues in the binding of peptides to HLAâ€A*1101 molecules. Tissue Antigens, 1998, 52, 501-509.	1.0	29

~		_
$(\Box T \Delta^{-}$	TION	REDUBL
		ICLI ORI

#	Article	IF	CITATIONS
73	Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. Immunological Reviews, 1998, 164, 37-51.	6.0	55
74	Mechanism for the development of pyothoraxâ€associated lymphoma. Pathology International, 1998, 48, 653-664.	1.3	26
75	Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Seminars in Immunopathology, 1998, 20, 455-491.	4.0	41
76	Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Biomedicine and Pharmacotherapy, 1998, 52, 13-25.	5.6	14
77	Chicken CD4, CD8alphabeta, and CD8alphaalpha T cell co-receptor molecules. Poultry Science, 1998, 77, 1858-1873.	3.4	50
78	Herpesvirus Evasion of the Immune System. Current Topics in Microbiology and Immunology, 1998, 232, 149-177.	1.1	56
79	Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virus–Positive Hodgkin's Disease. Blood, 1998, 92, 2477-2483.	1.4	133
80	The Molecular Evolutionary History of the Herpesviruses. , 1999, , 441-465.		54
81	Drift and Conservatism in RNA Virus Evolution. , 1999, , 115-140.		9
82	Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkin's Disease. Blood, 1999, 94, 442-447.	1.4	70
83	The Molecular Epidemiology and Evolution of Epsteinâ€Barr Virus: Sequence Variation and Genetic Recombination in the Latent Membrane Proteinâ€1 Gene. Journal of Infectious Diseases, 1999, 179, 763-774.	4.0	82
84	The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic Tâ€lymphocyte responses. Immunology, 1999, 96, 411-415.	4.4	22
85	Human pathogen subversion of antigen presentation. Immunological Reviews, 1999, 168, 199-215.	6.0	73
86	The Evolution of Mating Preferences and Major Histocompatibility Complex Genes. American Naturalist, 1999, 153, 145-164.	2.1	677
87	Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology, 1999, 30, 1037-1044.	7.3	53
88	Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. European Journal of Immunology, 1999, 29, 1292-1303.	2.9	48
89	Comparative analysis of Epstein-Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: Implications on virus strain selection in malignancy. , 1999, 80, 356-364.		71
90	Epstein-Barr Virus (EBV) Nuclear Antigen (EBNA)-4 Mutation in EBV-Associated Malignancies in Three Different Populations. American Journal of Pathology, 1999, 155, 941-947.	3.8	20

#	Article	IF	CITATIONS
91	The Epstein-Barr virus and its association with human cancers. Journal of Clinical Pathology, 1999, 52, 307-322.	1.9	133
92	Sequences of cytotoxic T-lymphocyte epitopes in the Epstein-Barr virus (EBV) nuclear antigen-3B gene in a Japanese population with or without EBV-positive lymphoid malignancies. International Journal of Cancer, 2000, 88, 626-632.	5.1	12
93	Do infectious diseases drive MHC diversity?. Microbes and Infection, 2000, 2, 1335-1341.	1.9	146
94	Genomic variability of equine herpesvirus-5. Archives of Virology, 2000, 145, 1359-1371.	2.1	27
95	Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood, 2000, 96, 443-451.	1.4	262
96	Immunological Aspects of the Pathogenesis of Tumors Associated with Epstein-Barr Virus: Vaccines for Prevention and Therapy. Contributions To Oncology / Beitrage Zur Onkologie, 2000, 55, 275-285.	0.1	0
97	Definition of the Mamu A*01 Peptide Binding Specificity: Application to the Identification of Wild-Type and Optimized Ligands from Simian Immunodeficiency Virus Regulatory Proteins. Journal of Immunology, 2000, 165, 6387-6399.	0.8	47
98	Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals. Gut, 2000, 47, 137-143.	12.1	22
99	Immunological transitions in response to antigenic mutation during viral infection. International Immunology, 2000, 12, 1371-1380.	4.0	6
100	Antigenic Drift in the Influenza A Virus (H3N2) Nucleoprotein and Escape from Recognition by Cytotoxic T Lymphocytes. Journal of Virology, 2000, 74, 6800-6807.	3.4	164
101	Supermotif peptide binding and degeneracy of MHC: peptide recognition in an EBV peptide-specific CTL response with highly restricted TCR usage. Human Immunology, 2000, 61, 972-984.	2.4	6
102	Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated Diseases. Annual Review of Microbiology, 2000, 54, 19-48.	7.3	182
103	Cancer processes in immunodeficient populations. European Journal of Cancer, 2001, 37, 1202-1208.	2.8	4
104	Linfomas cutáneos de células citotóxicas. Piel, 2001, 16, 193-197.	0.0	2
106	Gammaherpesviral infections and neoplasia in immunocompromised populations. , 2001, , 213-232.		0
107	How selection shapes variation of the human major histocompatibility complex: a review. Annals of Human Genetics, 2001, 65, 1-26.	0.8	299
108	CD4+ T-cell–epitope escape mutant virus selected in vivo. Nature Medicine, 2001, 7, 795-800.	30.7	72
109	Evolution and transmission of stable CTL escape mutations in HIV infection. Nature, 2001, 412, 334-338.	27.8	523

		CITATION REPORT		
#	Article		IF	CITATIONS
110	Evasion of the immune system by tumor viruses. Perspectives in Medical Virology, 200	1,,413-449.	0.1	2
111	In Vivo Selection of a Lymphocytic Choriomeningitis Virus Variant That Affects Recogn GP33-43 Epitope by H-2D b but Not H-2K b. Journal of Virology, 2001, 75, 5099-5107.	ition of the	3.4	61
112	Diagnostic Testing in Epstein-Barr Virus Infection. Clinical Chemistry and Laboratory M 39, 789-94.	edicine, 2001,	2.3	4
113	Molecular evolution of the <i>γ–Herpesvirinae</i> . Philosophical Transactions of the Biological Sciences, 2001, 356, 421-435.	e Royal Society B:	4.0	104
114	The immunology of Epstein–Barr virus infection. Philosophical Transactions of the Ro Biological Sciences, 2001, 356, 475-488.	oyal Society B:	4.0	60
115	Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chr Infection. Journal of Experimental Medicine, 2001, 193, 181-194.	onic HIV	8.5	249
116	Toward Improved Evaluation of Cytotoxic T-Lymphocyte (CTL)-Inducing HIV Vaccines ir Research and Human Retroviruses, 2002, 18, 737-739.	ו Thailand. AIDS	1.1	2
117	Sequence Variation in a Newly Identified HLA-B35-Restricted Epitope in the Influenza A Nucleoprotein Associated with Escape from Cytotoxic T Lymphocytes. Journal of Virolo 2567-2572.	. Virus gy, 2002, 76,	3.4	103
118	Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngea Taiwan. Journal of the National Cancer Institute, 2002, 94, 1780-1789.	I Carcinoma in	6.3	193
119	Biology and Pathogenesis of Lymphocytic Choriomeningitis Virus Infection. Current To Microbiology and Immunology, 2002, 263, 83-117.	pics in	1.1	152
120	Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Lev 296, 1439-1443.	vel. Science, 2002,	12.6	701
121	Manipulation of immune responses by Epstein–Barr virus. Virus Research, 2002, 88,	71-86.	2.2	31
122	A panel of MHC class I restricted viral peptides for use as a quality control for vaccine t assays. Journal of Immunological Methods, 2002, 260, 157-172.	rial ELISPOT	1.4	299
123	Evidence of Diversifying Selection in Human Papillomavirus Type 16 E6 But Not E7 One of Molecular Evolution, 2002, 55, 491-499.	cogenes. Journal	1.8	27
124	The association of specific HLA class I and II alleles with type 1 diabetes among Filipino Antigens, 2002, 59, 452-469.	s. Tissue	1.0	62
125	Epstein-Barr Virus Nuclear Antigen (EBNA)-1 Carboxy-Terminal and EBNA-4 Sequence P Nasal Natural Killer/T-Cell Lymphoma in the United States. Laboratory Investigation, 20	olymorphisms in 02, 82, 957-962.	3.7	8
126	Epstein–Barr virus: Induction and control of cell transformation. Journal of Cellular P 2003, 196, 207-218.	hysiology,	4.1	69
127	Gradual adaptation of HIV to human host populations: good or bad news?. Nature Med 1359-1362.	licine, 2003, 9,	30.7	61

#	Article	IF	CITATIONS
128	HLA-A11-Restricted Epitope Polymorphism among Epstein-Barr Virus Strains in the Highly HLA-A11-Positive Chinese Population: Incidence and Immunogenicity of Variant Epitope Sequences. Journal of Virology, 2003, 77, 11507-11516.	3.4	32
129	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Advances in Cancer Research, 2003, 87, 127-157.	5.0	33
130	Latent Gene Sequencing Reveals Familial Relationships among Chinese Epstein-Barr Virus Strains and Evidence for Positive Selection of A11 Epitope Changes. Journal of Virology, 2003, 77, 11517-11530.	3.4	39
132	Frequent Transmission of Cytotoxic-T-Lymphocyte Escape Mutants of Human Immunodeficiency Virus Type 1 in the Highly HLA-A24-Positive Japanese Population. Journal of Virology, 2004, 78, 8437-8445.	3.4	41
133	A Mutation in the HLA-B * 2705-Restricted NP 383-391 Epitope Affects the Human Influenza A Virus-Specific Cytotoxic T-Lymphocyte Response In Vitro. Journal of Virology, 2004, 78, 5216-5222.	3.4	72
134	Amino acid changes in functional domains of latent membrane protein 1 of Epstein–Barr virus in nasopharyngeal carcinoma of southern China and Taiwan: prevalence of an HLA A2-restricted â€~epitope-loss variant'. Journal of General Virology, 2004, 85, 2023-2034.	2.9	30
135	HIV-1 Tat Protein Modulates the Generation of Cytotoxic T Cell Epitopes by Modifying Proteasome Composition and Enzymatic Activity. Journal of Immunology, 2004, 173, 3838-3843.	0.8	101
136	Parasites and individual major histocompatibility complex diversity—an optimal choice?. Microbes and Infection, 2004, 6, 1110-1116.	1.9	48
137	Epstein-Barr Virus Primary Mismatching and HLA Matching: Key Risk Factors for Post Lung Transplant Lymphoproliferative Disease. Transplantation, 2004, 78, 205-210.	1.0	29
138	The Vertebrate Immune System. , 2004, , 1-56.		0
138 140	The Vertebrate Immune System. , 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84.	3.0	0 6
138 140 141	The Vertebrate Immune System., 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936.	3.0 7.0	0 6 18
138 140 141 142	The Vertebrate Immune System., 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936. The importance of immune gene variability (MHC) in evolutionary ecology and conservation., 2005, 2, 16.	3.0	0 6 18 647
138 140 141 142 144	The Vertebrate Immune System., 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936. The importance of immune gene variability (MHC) in evolutionary ecology and conservation., 2005, 2, 16. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902.	3.0 7.0 8.5	0 6 18 647 220
 138 140 141 142 144 145 	The Vertebrate Immune System., 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936. The importance of immune gene variability (MHC) in evolutionary ecology and conservation., 2005, 2, 16. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut, 2006, 55, 266-274.	3.0 7.0 8.5 12.1	0 6 18 647 220 88
 138 140 141 142 144 145 146 	The Vertebrate Immune System., 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936. The importance of immune gene variability (MHC) in evolutionary ecology and conservation., 2005, 2, 16. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut, 2006, 55, 266-274. CD8 T-cell Immunodominance, Repertoire, and Memory., 2006, , 109-145.	 3.0 7.0 8.5 12.1 	0 6 18 647 220 88
 138 140 141 142 142 144 145 146 147 	The Vertebrate Immune System. , 2004, , 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936. The importance of immune gene variability (MHC) in evolutionary ecology and conservation. , 2005, 2, 16. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut, 2006, 55, 266-274. CD8 T-cell Immunodominance, Repertoire, and Memory. , 2006, , 109-145. Genetic variation in MHC class II expression and interactions with MHC sequence polymorphism in threeã€spined sticklebacks. Molecular Ecology, 2006, 15, 1153-1164.	3.0 7.0 8.5 12.1 3.9	0 6 18 647 220 88 88
 138 140 141 142 142 144 145 146 147 148 	The Vertebrate Immune System., 2004,, 1-56. Self-peptide/MHC and TCR antagonism: Physiological role and therapeutic potential. Cellular Immunology, 2005, 233, 75-84. Eunctional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Journal of Biomedical Science, 2005, 12, 925-936. The importance of immune gene variability (MHC) in evolutionary ecology and conservation., 2005, 2, 16. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA Journal of Experimental Medicine, 2005, 201, 891-902. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut, 2006, 55, 266-274. CD8 T-cell Immunodominance, Repertoire, and Memory., 2006, 109-145. Genetic variation in MHC class II expression and interactions with MHC sequence polymorphism in threea€spined sticklebacks. Molecular Ecology, 2006, 15, 1153-1164. New Epitope Peptides Derived from Hepatitis C Virus (HCV) 2a Which Have the Capacity to Induce Cytotoxic T Lymphocytes in HLAãcA2 ^{+ (/sup> HCVàcHrected Patients. Microbiology and Immunology, 2006, 50, 857-865.}	3.0 7.0 8.5 12.1 3.9 1.4	0 6 18 647 220 88 88 4 2

#	Article	IF	CITATIONS
149	Repetitive Olfactory Exposure to the Biologically Significant Steroid Androstadienone Causes a Hedonic Shift and Gender Dimorphic Changes in Olfactory-Evoked Potentials. Neuropsychopharmacology, 2007, 32, 1822-1829.	5.4	31
150	Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein–Barr virus latent membrane protein 2. Virology, 2007, 361, 253-262.	2.4	10
151	The MHC paradigm: genetic variation and complex disease. , 2007, , 142-151.		0
152	Innate versus adaptive immunity in sticklebacks: evidence for trade-offs from a selection experiment. Evolutionary Ecology, 2007, 21, 473-483.	1.2	35
153	Maintenance of genetic variation in sexual ornaments: a review of the mechanisms. Genetica, 2008, 134, 113-127.	1.1	88
154	Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunological Reviews, 2008, 223, 317-333.	6.0	82
155	Understanding the immunopathogenesis of chronic hepatitis B virus: An Asian prospective. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 833-843.	2.8	32
156	MHC-mediated mate choice increases parasite resistance in salmon. Proceedings of the Royal Society B: Biological Sciences, 2008, 275, 1397-1403.	2.6	111
157	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. Journal of Virology, 2008, 82, 10986-10997.	3.4	114
158	The Spectrum of Epstein-Barr Virus-Associated Lymphoproliferative Disease in Korea: Incidence of Disease Entities by Age Groups. Journal of Korean Medical Science, 2008, 23, 185.	2.5	45
159	Does intra-individual major histocompatibility complex diversity keep a golden mean?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2009, 364, 117-128.	4.0	146
160	Association of human leukocyte antigens with nasopharyngeal carcinoma in high-risk multiplex families in Taiwan. Human Immunology, 2009, 70, 910-914.	2.4	24
161	The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk. Molecular Biology Reports, 2010, 37, 119-126.	2.3	18
162	Shedding dynamics of Epstein-Barr virus: A type 1 carcinogen. Archives of Oral Biology, 2010, 55, 639-647.	1.8	21
163	TEMPORAL VARIATION AT THE MHC CLASS IIB IN WILD POPULATIONS OF THE GUPPY (<i>POECILIA) Tj ETQq0 0</i>	0 rgBT /Ov	verlock 10 Tf
164	Polymorphisms of HLA-A and HLA-B genes in genetic susceptibility to esophageal carcinoma in Chaoshan Han Chinese. Ecological Management and Restoration, 2010, 23, 46-52.	0.4	7
165	Widespread sequence variation in the Epstein-Barr virus latent membrane protein 2A gene among northern Chinese isolates. Journal of General Virology, 2010, 91, 2564-2573.	2.9	14
166	Constraints within major histocompatibility complex class I restricted peptides: Presentation and consequences for T-cell recognition. Proceedings of the National Academy of Sciences of the United	7.1	58

#	Article	IF	CITATIONS
167	Does reduced MHC diversity decrease viability of vertebrate populations?. Biological Conservation, 2010, 143, 537-544.	4.1	201
168	Major histocompatibility complex DRB genes and blood parasite loads in fragmented populations of the spotted suslik Spermophilus suslicus. Mammalian Biology, 2011, 76, 672-677.	1.5	9
169	Sources of diversity in T cell epitope discovery. Frontiers in Bioscience - Landmark, 2011, 16, 3014.	3.0	11
170	Patterns of Predicted T-Cell Epitopes Associated with Antigenic Drift in Influenza H3N2 Hemagglutinin. PLoS ONE, 2011, 6, e26711.	2.5	9
171	Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic. Aids, 2011, 25, 1691-1700.	2.2	25
172	Ethnoepidemiology of HTLVâ€1 related diseases: Ethnic determinants of HTLVâ€1 susceptibility and its worldwide dispersal. Cancer Science, 2011, 102, 295-301.	3.9	73
173	The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans. Science, 2011, 334, 89-94.	12.6	441
174	Specific Mutation of a Gammaherpesvirus-Expressed Antigen in Response to CD8 T Cell Selection <i>In Vivo</i> . Journal of Virology, 2012, 86, 2887-2893.	3.4	4
175	Epstein-Barr Virus Isolates Retain Their Capacity To Evade T Cell Immunity through BNLF2a despite Extensive Sequence Variation. Journal of Virology, 2012, 86, 572-577.	3.4	14
176	T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clinical and Experimental Immunology, 2013, 172, 254-262.	2.6	8
177	The genome of murine cytomegalovirus is shaped by purifying selection and extensive recombination. Virology, 2013, 435, 258-268.	2.4	32
178	Conditional ligands for <scp>A</scp> sian <scp>HLA</scp> variants facilitate the definition of <scp>CD</scp> 8 ⁺ <scp>T</scp> â€cell responses in acute and chronic viral diseases. European Journal of Immunology, 2013, 43, 1109-1120.	2.9	49
179	Survey of Epstein Barr Virus (EBV) Immunogenic Proteins and their Epitopes: Implications for Vaccine Preparation. Recent Patents on Anti-infective Drug Discovery, 2014, 9, 62-76.	0.8	13
180	Epstein–barr virus diversity in immunocompetent healthy persons: Reassessment of the distribution of genetic variants. Journal of Medical Virology, 2014, 86, 301-305.	5.0	4
181	Rare Lymphomas. , 2014, , .		0
182	Human Leukocyte Antigen Type and Posttransplant Lymphoproliferative Disorder. Transplantation, 2015, 99, 1220-1225.	1.0	22
183	Epstein–Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Types. Current Topics in Microbiology and Immunology, 2015, 390, 119-148.	1.1	27
184	Paleogenetics and Past Infections: the Two Faces of the Coin of Human Immune Evolution. , 2016, , 21-27.		0

#	Article	IF	CITATIONS
185	Paleogenetics and Past Infections: the Two Faces of the Coin of Human Immune Evolution. Microbiology Spectrum, 2016, 4, .	3.0	6
186	Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. Journal of Leukocyte Biology, 2016, 100, 545-557.	3.3	15
187	Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative Genomics. Genome Biology and Evolution, 2016, 8, 3284-3291.	2.5	29
188	Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach. Modern Pathology, 2017, 30, S1-S26.	5.5	61
189	Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 Revision of the World Health Organization Classification. Journal of the Formosan Medical Association, 2017, 116, 620-625.	1.7	25
190	Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer. Lung Cancer, 2017, 112, 169-175.	2.0	21
191	Evolution of the Human Leukocyte Antigen System. , 2017, , 211-219.		0
192	Reproductive Strategy Inferred from Major Histocompatibility Complex-Based Inter-Individual, Sperm-Egg, and Mother-Fetus Recognitions in Giant Pandas (Ailuropoda melanoleuca). Cells, 2019, 8, 257.	4.1	10
193	Differential escape of <scp>HCV</scp> from <scp>CD</scp> 8 ⁺ T cell selection pressure between China and Germany depends on the presenting <scp>HLA</scp> class I molecule. Journal of Viral Hepatitis, 2019, 26, 73-82.	2.0	4
194	SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. Vaccines, 2020, 8, 444.	4.4	11
195	In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. PLoS Pathogens, 2020, 16, e1008607.	4.7	13
196	Seltene Erkrankungen der Nase, der NasennebenhĶhlen und der vorderen SchÄ d elbasis. Laryngo- Rhino- Otologie, 2021, 100, S1-S44.	0.2	3
197	Immunology and Immunity Studied with Viruses. Novartis Foundation Symposium, 1997, 204, 105-129.	1.1	8
198	Cellular Adoptive Immunotherapy after Bone Marrow Transplantation. Cancer Treatment and Research, 1995, 76, 337-369.	0.5	19
199	EBV and Malignant Lymphoma with Special Emphasis on Pyothorax-Associated Lymphoma. Current Topics in Microbiology and Immunology, 2001, 258, 103-120.	1.1	4
200	Peptide-Major Histocompatibility Complex Class I Complex: From the Structural and Molecular Basis to Pharmacological Principles and Therapeutic Applications. Current Topics in Microbiology and Immunology, 1998, 232, 75-97.	1.1	5
201	The Class I-Restricted Cytotoxic T Lymphocyte Response to Predetermined Epitopes in the Hepatitis B and C Viruses. Current Topics in Microbiology and Immunology, 1994, 189, 169-186.	1.1	31
202	Reconstitution of Immunity by Adoptive Immunotherapy with T Cells. , 1999, , 137-177.		1

#	Article	IF	CITATIONS
203	The role of repetitive DNA sequences in the size variation of Epstein–Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. Journal of General Virology, 1995, 76, 779-790.	2.9	67
204	Epstein–Barr virus latent gene sequences as geographical markers of viral origin: unique EBNA3 gene signatures identify Japanese viruses as distinct members of the Asian virus family. Journal of General Virology, 2011, 92, 1032-1043.	2.9	14
205	HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. Journal of Virology, 1993, 67, 7428-7435.	3.4	180
206	Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. Journal of Virology, 1993, 67, 7522-7532.	3.4	291
207	Virus-induced immunosuppression: kinetic analysis of the selection of a mutation associated with viral persistence. Journal of Virology, 1994, 68, 7367-7373.	3.4	43
208	The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. Journal of Virology, 1994, 68, 7918-7926.	3.4	65
209	5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. Journal of Virology, 1995, 69, 8011-8019.	3.4	56
210	Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. Journal of Virology, 1995, 69, 2187-2193.	3.4	89
211	Tissue distribution of Epstein-Barr virus genotypes. Journal of Virology, 1996, 70, 7301-7305.	3.4	36
212	Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants. Journal of Virology, 1996, 70, 7306-7311.	3.4	11
213	Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. Journal of Virology, 1996, 70, 2490-2496.	3.4	52
214	Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. Journal of Virology, 1997, 71, 8340-8346.	3.4	60
215	Immediate-Early Transactivator Rta of Epstein-Barr Virus (EBV) Shows Multiple Epitopes Recognized by EBV-Specific Cytotoxic T Lymphocytes. Journal of Virology, 1998, 72, 8644-8649.	3.4	49
216	The Cytotoxic T-Cell Response to Herpes Simplex Virus Type 1 Infection of C57BL/6 Mice Is Almost Entirely Directed against a Single Immunodominant Determinant. Journal of Virology, 1999, 73, 7619-7626.	3.4	136
217	Immune regulation in Epstein-Barr virus-associated diseases. Microbiological Reviews, 1995, 59, 387-405.	10.1	176
218	HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release Journal of Clinical Investigation, 1995, 96, 2311-2321.	8.2	300
219	Cytotoxic T cells and viral hepatitis Journal of Clinical Investigation, 1997, 99, 1472-1477.	8.2	336
220	Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection Journal of Clinical Investigation, 1998, 101, 2559-2566.	8.2	144

#	Article	IF	CITATIONS
221	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virus–Related Hodgkin's Disease. Blood, 1997, 89, 1723-1731.	1.4	15
222	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virus–Related Hodgkin's Disease. Blood, 1997, 89, 1723-1731.	1.4	46
223	Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virus–Positive Hodgkin's Disease. Blood, 1998, 92, 2477-2483.	1.4	8
224	Hepatitis C Virus Infection Involves CD34+Hematopoietic Progenitor Cells in Hepatitis C Virus Chronic Carriers. Blood, 1998, 92, 3328-3337.	1.4	82
225	Hepatitis C Virus Infection Involves CD34+Hematopoietic Progenitor Cells in Hepatitis C Virus Chronic Carriers. Blood, 1998, 92, 3328-3337.	1.4	22
226	Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkin's Disease. Blood, 1999, 94, 442-447.	1.4	15
227	Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood, 2000, 96, 443-451.	1.4	22
228	Sequence Variations of Latent Membrane Protein 2A in Epstein-Barr Virus-Associated Gastric Carcinomas from Guangzhou, Southern China. PLoS ONE, 2012, 7, e34276.	2.5	11
229	MHC genetic diversity and avian malaria prevalence in Mokoia Island saddlebacks. , 2016, 40, 351-360.		5
230	Epstein-barr virus immortalization and latency. Frontiers in Bioscience - Landmark, 1999, 4, d346.	3.0	39
231	GWAS signals across the HLA regions: revealing a clue for common etiology underlying infectious tumors and other immunity diseases. Chinese Journal of Cancer, 2011, 30, 226-230.	4.9	10
232	The Generation and Selection of Major Histocompatibility Complex Polymorphisms. , 2000, , 171-178.		0
233	Contrasting patterns of MHC and microsatellite diversity in social and solitary tuco-tucos (Rodentia:) Tj ETQq0 0	0 rgBT /Ov	verlock 10 Tf
234	HLA and Infectious Diseases. , 2000, , 299-326.		1
235	Recognition of human tumours: viral antigens as immunological targets for cytotoxic T cells. , 2001, , 123-145.		0
236	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Advances in Cancer Research, 2003, 87, 127-157.	5.0	10
237	Potential Antigenic Targets on Epstein ―Barr Virusâ€Associated Tumours and the Host Response. Novartis Foundation Symposium, 1994, 187, 4-20.	1.1	12
238	Extranodal NK/T-Cell Lymphoma, Nasal Type. , 2014, , 121-131.		0

#	Article	IF	CITATIONS
239	Tumour Immunology. , 1995, , 203-221.		0
240	Virus induced cancer: The lesson of Epstein—Barr virus. , 1996, , 161-175.		Ο
241	The Cytolytic T Cell Response to HIV-1. , 1996, , 55-64.		1
242	The MHC in Host-Pathogen Evolution. , 1996, , 243-260.		0
243	The role of infectious disease, inbreeding and mating preferences in maintaining MHC genetic diversity: an experimental test. , 1997, , 99-108.		0
244	Immunogenetics of the Host Response to Viral Infections. , 0, , 421-436.		0
258	Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. American Journal of Human Genetics, 1995, 57, 1436-44.	6.2	99
259	Detection and characterization of Epstein-Barr virus in clinical specimens. American Journal of Pathology, 1994, 145, 239-52.	3.8	88
260	Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy. International Journal of Clinical and Experimental Pathology, 2008, 1, 185-97.	0.5	9
261	Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven. Frontiers in Immunology, 2021, 12, 796379.	4.8	2
262	Evolutionary pressures rendered by animal husbandry practices for avian influenza viruses to adapt to humans. IScience, 2022, 25, 104005.	4.1	2
263	Human herpesvirus diversity is altered in HLA class I binding peptides. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123248119.	7.1	3
264	The Clonal Composition of a Peptide-Specific Oligoclonal CTL Repertoire Selected in Response to Persistent EBV Infection Is Stable Over Time. Journal of Immunology, 1998, 161, 594-601.	0.8	53
265	Recognition of Two Overlapping CTL Epitopes in HIV-1 p17 by CTL from a Long-Term Nonprogressing HIV-1-Infected Individual. Journal of Immunology, 1998, 161, 4875-4881.	0.8	14
266	Polyclonality and Multispecificity of the CTL Response to a Single Viral Epitope. Journal of Immunology, 1998, 161, 5842-5850.	0.8	62
267	A Re-Evaluation of the Frequency of CD8+ T Cells Specific for EBV in Healthy Virus Carriers. Journal of Immunology, 1999, 162, 1827-1835.	0.8	396
268	Identification of Three HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in the Cytomegalovirus Protein pp65 That Are Conserved Between Eight Strains of the Virus. Journal of Immunology, 1999, 163, 5512-5518.	0.8	116
269	The impact of HLA polymorphism on herpesvirus infection and disease. Immunogenetics, 0, , .	2.4	1

#	ARTICLE	IF	CITATIONS
270	Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice. Nature Communications, 2023, 14, .	12.8	4
271	Epstein-Barr virus–encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma. Blood, 2024, 143, 429-443.	1.4	2
272	Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: Assessment of interaction and mediation. Cell Genomics, 2024, 4, 100474.	6.5	0